News | April 08, 2025
NATCO Pharma updates on legal proceedings on Risdiplam launch in India
NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court
NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court
Jadhav has completed his B.Pharmacy and is having 30+ years of rich experience in operation management in pharmaceutical Industry
TFOS is indicated for the treatment of pulmonary arterial hypertension
Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma
He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Natco Pharma intends to defend the matter accordingly
Subscribe To Our Newsletter & Stay Updated
